Skip to main content
Erschienen in: Cancer Chemotherapy and Pharmacology 3/2004

01.03.2004 | Original Article

Activity of docetaxel in paclitaxel-resistant ovarian cancer cells

verfasst von: Shinya Sato, Junzo Kigawa, Yasunobu Kanamori, Hiroaki Itamochi, Tetsuro Oishi, Muneaki Shimada, Takahiro Iba, Jun Naniwa, Kazunori Uegaki, Naoki Terakawa

Erschienen in: Cancer Chemotherapy and Pharmacology | Ausgabe 3/2004

Einloggen, um Zugang zu erhalten

Abstract

Purpose

The aim of this study was to determine the behavior of docetaxel (DTX) in ovarian cancer cells resistant to paclitaxel (PTX).

Methods

We used human ovarian adenocarcinoma cell lines KF, KFTx (PTX-resistant KF), SK-OV-3, and HAC-2. The sensitivity of the cells to PTX or DTX was determined by the MTT assay. Cellular accumulation of PTX and DTX was measured by high-performance liquid chromatography. mRNA of MDR-1 was detected by RT-PCR. Cell cycle distribution was determined by flow cytometry after exposure to the IC50 of each drug. Bcl-2 phosphorylation was determined by Western blot analysis. Activity for tubulin polymerization of each drug was examined by a β-tubulin polymerization assay.

Results

KFTx cells had a 5.5-fold greater resistance to PTX and a 7.3-fold greater resistance to DTX than KF cells, indicating that KFTx cells had acquired cross-resistance to DTX. SK-OV-3 cells were sensitive and HAC-2 cells were resistant to both PTX and DTX. The gene expression of MDR-1 increased after exposure to DTX in KF and KFTx cells. Residual cellular accumulation of PTX and DTX was significantly lower in KFTx cells than in KF cells. In contrast, MDR-1 expression was not detected in SK-OV-3 and HAC-2 cells. Flow cytometric analysis indicated no differences in alterations of cell cycle distribution following exposure to the two drugs. Bcl-2 phosphorylation occurred after exposure to DTX at a concentration equivalent to the clinical dose, but did not occur after exposure to PTX in KFTx cells. In HAC-2 cells, Bcl-2 phosphorylation was not detected after exposure to DTX or PTX at concentrations equivalent to the clinical doses. DTX showed greater tubulin polymerization activity than PTX in KFTx cells. β-tubulin polymerization did not correlate with the concentration of PTX or DTX, suggesting that alteration in the tubulin reaction might contribute to the resistance in HAC-2 cells.

Conclusions

The present study suggests that the mechanisms involved in cytotoxicity of and resistance to PTX and DTX do not differ, but DTX has a greater cytotoxic potential in PTX-resistant cells with an efflux system.
Literatur
1.
Zurück zum Zitat Basu A, Haldar S (1998) Microtubule-damaging drugs triggered bcl2 phosphorylation-requirement of phosphorylation on both serine-70 and serine-87 residues of bcl2 protein. Int J Oncol 13:659PubMed Basu A, Haldar S (1998) Microtubule-damaging drugs triggered bcl2 phosphorylation-requirement of phosphorylation on both serine-70 and serine-87 residues of bcl2 protein. Int J Oncol 13:659PubMed
2.
Zurück zum Zitat Benjapibal M, Kudelka AP, Vasuratna A, Edwards CL, Verschraegen CF, Valero V, Vadhan-Raj S, Kavanagh JJ (1998) Docetaxel and cyclophosphamide induced remission in platinum and paclitaxel refractory ovarian cancer. Anticancer Drugs 9:577PubMed Benjapibal M, Kudelka AP, Vasuratna A, Edwards CL, Verschraegen CF, Valero V, Vadhan-Raj S, Kavanagh JJ (1998) Docetaxel and cyclophosphamide induced remission in platinum and paclitaxel refractory ovarian cancer. Anticancer Drugs 9:577PubMed
3.
Zurück zum Zitat Blagosklonny MV, Giannakakou P, El-Deiry WS, Kingston DG, Higgs PI, Neckers L, Fojo T (1997) Raf-1/bcl-2 phosphorylation: a step from microtubule damage to cell death. Cancer Res 57:130PubMed Blagosklonny MV, Giannakakou P, El-Deiry WS, Kingston DG, Higgs PI, Neckers L, Fojo T (1997) Raf-1/bcl-2 phosphorylation: a step from microtubule damage to cell death. Cancer Res 57:130PubMed
4.
Zurück zum Zitat Britten RA, Klein K (2000) Differential impact of Raf-1 kinase activity on tumor cell resistance to paclitaxel and docetaxel. Anticancer Drugs 11:439CrossRefPubMed Britten RA, Klein K (2000) Differential impact of Raf-1 kinase activity on tumor cell resistance to paclitaxel and docetaxel. Anticancer Drugs 11:439CrossRefPubMed
5.
Zurück zum Zitat Chomcynski P, Sacchi N (1987) Single-step method of DNA isolation by acid guanidinium thiocyanate-chloroform extraction. Anal Biochem 162:156PubMed Chomcynski P, Sacchi N (1987) Single-step method of DNA isolation by acid guanidinium thiocyanate-chloroform extraction. Anal Biochem 162:156PubMed
6.
Zurück zum Zitat Christen RD, Jekunen AP, Jones JA, Thiebaut F, Shalinsky DR, Howell SB (1993) In vitro modulation of cisplatin accumulation in human ovarian carcinoma cells by pharmacologic alteration of microtubules. J Clin Invest 92:431PubMed Christen RD, Jekunen AP, Jones JA, Thiebaut F, Shalinsky DR, Howell SB (1993) In vitro modulation of cisplatin accumulation in human ovarian carcinoma cells by pharmacologic alteration of microtubules. J Clin Invest 92:431PubMed
7.
9.
Zurück zum Zitat Dumontet C, Sikic BI (1999) Mechanisms of action of and resistance to antitubulin agents: microtubule dynamics, drug transport, and cell death. J Clin Oncol 17:1061PubMed Dumontet C, Sikic BI (1999) Mechanisms of action of and resistance to antitubulin agents: microtubule dynamics, drug transport, and cell death. J Clin Oncol 17:1061PubMed
10.
Zurück zum Zitat Engblom P, Rantanen V, Kulmala J, Heiskanen J, Grenman S (1997) Taxane sensitivity of ovarian carcinoma in vitro. Anticancer Res 17:2475PubMed Engblom P, Rantanen V, Kulmala J, Heiskanen J, Grenman S (1997) Taxane sensitivity of ovarian carcinoma in vitro. Anticancer Res 17:2475PubMed
11.
Zurück zum Zitat Giannakakou P, Poy G, Zhan Z, Knutsen T, Blagosklonny MV, Fojo T (2000) Paclitaxel selects for mutant or pseudo-null p53 in drug resistance associated with tubulin mutations in human cancer. Oncogene 19:3078CrossRefPubMed Giannakakou P, Poy G, Zhan Z, Knutsen T, Blagosklonny MV, Fojo T (2000) Paclitaxel selects for mutant or pseudo-null p53 in drug resistance associated with tubulin mutations in human cancer. Oncogene 19:3078CrossRefPubMed
12.
Zurück zum Zitat Hortobagyi GN (1999) Recent progress in the clinical development of docetaxel (Taxotere). Semin Oncol 26 [3 Suppl 9]:32 Hortobagyi GN (1999) Recent progress in the clinical development of docetaxel (Taxotere). Semin Oncol 26 [3 Suppl 9]:32
14.
Zurück zum Zitat Huizing MT, Keung AC, Rosing H, van der Kuij V, ten Bokkel Huinink, WW Mandjes IM, Dubbelman AC, Pinedo HM, Beijnen JH (1993) Pharmacokinetics of paclitaxel and metabolites in a randomized comparative study in platinum-pretreated ovarian cancer patients. J Clin Oncol 11:2127PubMed Huizing MT, Keung AC, Rosing H, van der Kuij V, ten Bokkel Huinink, WW Mandjes IM, Dubbelman AC, Pinedo HM, Beijnen JH (1993) Pharmacokinetics of paclitaxel and metabolites in a randomized comparative study in platinum-pretreated ovarian cancer patients. J Clin Oncol 11:2127PubMed
15.
Zurück zum Zitat Kamazawa S, Kigawa J, Minagawa Y, Itamochi H, Shimada M, Takahashi M, Sato S, Akeshima R, Terakawa N (2000) Cellular efflux pump and interaction between cisplatin and paclitaxel in ovarian cancer cells. Oncology 59:329CrossRefPubMed Kamazawa S, Kigawa J, Minagawa Y, Itamochi H, Shimada M, Takahashi M, Sato S, Akeshima R, Terakawa N (2000) Cellular efflux pump and interaction between cisplatin and paclitaxel in ovarian cancer cells. Oncology 59:329CrossRefPubMed
16.
Zurück zum Zitat Kamazawa S, Kigawa J, Kanamori Y, Itamochi H, Sato S, Iba T, Terakawa N (2002) Multidrug resistance gene-1 is a useful predictor of paclitaxel-based chemotherapy for patients with ovarian cancer. Gynecol Oncol 86:171CrossRefPubMed Kamazawa S, Kigawa J, Kanamori Y, Itamochi H, Sato S, Iba T, Terakawa N (2002) Multidrug resistance gene-1 is a useful predictor of paclitaxel-based chemotherapy for patients with ovarian cancer. Gynecol Oncol 86:171CrossRefPubMed
17.
Zurück zum Zitat Kaye SB, Piccart M, Aapro M, Francis P, Kavanagh J (1997) Phase II trials of docetaxel (Taxotere) in advanced ovarian cancer—an updated overview. Eur J Cancer 33:2167CrossRefPubMed Kaye SB, Piccart M, Aapro M, Francis P, Kavanagh J (1997) Phase II trials of docetaxel (Taxotere) in advanced ovarian cancer—an updated overview. Eur J Cancer 33:2167CrossRefPubMed
18.
Zurück zum Zitat Longnecker SM, Donehower RC, Cates AE, Chen TL, Brundrett RB, Grochow LB, Ettinger DS, Colvin M (1987) High performance liquid chromatographic assay for taxol in human plasma and uterine and pharmacokinetics in phase I trial. Cancer Treat Rep 71:56 Longnecker SM, Donehower RC, Cates AE, Chen TL, Brundrett RB, Grochow LB, Ettinger DS, Colvin M (1987) High performance liquid chromatographic assay for taxol in human plasma and uterine and pharmacokinetics in phase I trial. Cancer Treat Rep 71:56
19.
Zurück zum Zitat Mosmann T (1983) Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J Immunol Methods 65:55PubMed Mosmann T (1983) Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J Immunol Methods 65:55PubMed
20.
Zurück zum Zitat Parness J, Horwitz SB (1981) Taxol binds to polymerized tubulin in vitro. J Cell Biol 91:479PubMed Parness J, Horwitz SB (1981) Taxol binds to polymerized tubulin in vitro. J Cell Biol 91:479PubMed
21.
Zurück zum Zitat Piccart MJ, Gore M, Ten Bokkel Huinink W, van Oosterom A, Verweij J, Wanders J, Franklin H, Bayssas M, Kaye S (1995) Docetaxel: an active new drug for treatment of advanced epithelial ovarian cancer. J Natl Cancer Inst 87:676PubMed Piccart MJ, Gore M, Ten Bokkel Huinink W, van Oosterom A, Verweij J, Wanders J, Franklin H, Bayssas M, Kaye S (1995) Docetaxel: an active new drug for treatment of advanced epithelial ovarian cancer. J Natl Cancer Inst 87:676PubMed
22.
Zurück zum Zitat Poruchynsky MS, Wang EE, Rudin CM, Blagosklonny MV, Fojo T (1998) Bcl-xL is phosphorylated in malignant cells following microtubule disruption. Cancer Res 58:3331PubMed Poruchynsky MS, Wang EE, Rudin CM, Blagosklonny MV, Fojo T (1998) Bcl-xL is phosphorylated in malignant cells following microtubule disruption. Cancer Res 58:3331PubMed
23.
Zurück zum Zitat Valero V (1996) Treatment of patients resistant to paclitaxel therapy. Anticancer Drugs 7 [Suppl 2]:17 Valero V (1996) Treatment of patients resistant to paclitaxel therapy. Anticancer Drugs 7 [Suppl 2]:17
24.
Zurück zum Zitat Veitia R, Bissery MC, Martinez C, Fellous A (1998) Tau expression in model adenocarcinomas correlates with docetaxel sensitivity in tumour-bearing mice. Br J Cancer 78:87 Veitia R, Bissery MC, Martinez C, Fellous A (1998) Tau expression in model adenocarcinomas correlates with docetaxel sensitivity in tumour-bearing mice. Br J Cancer 78:87
25.
Zurück zum Zitat Verschraegen CF, Sittisomwong T, Kudelka AP, Guedes ED, Steger M, Nelson-Taylor T, Vincent M, Rogers R, Atkinson EN, Kavanagh JJ (2000) Docetaxel for patients with paclitaxel-resistant Mullerian carcinoma. J Clin Oncol 18:2733PubMed Verschraegen CF, Sittisomwong T, Kudelka AP, Guedes ED, Steger M, Nelson-Taylor T, Vincent M, Rogers R, Atkinson EN, Kavanagh JJ (2000) Docetaxel for patients with paclitaxel-resistant Mullerian carcinoma. J Clin Oncol 18:2733PubMed
26.
Zurück zum Zitat Verweiji J, Claveli M, Chevalier B (1994) Paclitaxel (Taxol) and docetaxel (Taxotere): not simply two of a kind. Ann Oncol 5:495PubMed Verweiji J, Claveli M, Chevalier B (1994) Paclitaxel (Taxol) and docetaxel (Taxotere): not simply two of a kind. Ann Oncol 5:495PubMed
27.
Zurück zum Zitat Wang S, Wang Z, Boise L, Dent P, Grant S (1999) Loss of the bcl-2 phosphorylation loop domain increases resistance of human leukemia cells (U937) to paclitaxel-mediated mitochondrial dysfunction and apoptosis. Mol Cell Biol 19:8469PubMed Wang S, Wang Z, Boise L, Dent P, Grant S (1999) Loss of the bcl-2 phosphorylation loop domain increases resistance of human leukemia cells (U937) to paclitaxel-mediated mitochondrial dysfunction and apoptosis. Mol Cell Biol 19:8469PubMed
28.
Zurück zum Zitat Yamamoto K, Ichijo H, Korsmeyer SJ (1999) BCL-2 is phosphorylated and inactivated by an ASK1/Jun N-terminal protein kinase pathway normally activated at G(2)/M. Biochem Biophys Res Commun 259:67CrossRefPubMed Yamamoto K, Ichijo H, Korsmeyer SJ (1999) BCL-2 is phosphorylated and inactivated by an ASK1/Jun N-terminal protein kinase pathway normally activated at G(2)/M. Biochem Biophys Res Commun 259:67CrossRefPubMed
Metadaten
Titel
Activity of docetaxel in paclitaxel-resistant ovarian cancer cells
verfasst von
Shinya Sato
Junzo Kigawa
Yasunobu Kanamori
Hiroaki Itamochi
Tetsuro Oishi
Muneaki Shimada
Takahiro Iba
Jun Naniwa
Kazunori Uegaki
Naoki Terakawa
Publikationsdatum
01.03.2004
Verlag
Springer-Verlag
Erschienen in
Cancer Chemotherapy and Pharmacology / Ausgabe 3/2004
Print ISSN: 0344-5704
Elektronische ISSN: 1432-0843
DOI
https://doi.org/10.1007/s00280-003-0714-9

Weitere Artikel der Ausgabe 3/2004

Cancer Chemotherapy and Pharmacology 3/2004 Zur Ausgabe

Mehr Lebenszeit mit Abemaciclib bei fortgeschrittenem Brustkrebs?

24.05.2024 Mammakarzinom Nachrichten

In der MONARCHE-3-Studie lebten Frauen mit fortgeschrittenem Hormonrezeptor-positivem, HER2-negativem Brustkrebs länger, wenn sie zusätzlich zu einem nicht steroidalen Aromatasehemmer mit Abemaciclib behandelt wurden; allerdings verfehlte der numerische Zugewinn die statistische Signifikanz.

ADT zur Radiatio nach Prostatektomie: Wenn, dann wohl länger

24.05.2024 Prostatakarzinom Nachrichten

Welchen Nutzen es trägt, wenn die Strahlentherapie nach radikaler Prostatektomie um eine Androgendeprivation ergänzt wird, hat die RADICALS-HD-Studie untersucht. Nun liegen die Ergebnisse vor. Sie sprechen für länger dauernden Hormonentzug.

Das sind die führenden Symptome junger Darmkrebspatienten

Darmkrebserkrankungen in jüngeren Jahren sind ein zunehmendes Problem, das häufig längere Zeit übersehen wird, gerade weil die Patienten noch nicht alt sind. Welche Anzeichen Ärzte stutzig machen sollten, hat eine Metaanalyse herausgearbeitet.

„Überwältigende“ Evidenz für Tripeltherapie beim metastasierten Prostata-Ca.

22.05.2024 Prostatakarzinom Nachrichten

Patienten mit metastasiertem hormonsensitivem Prostatakarzinom sollten nicht mehr mit einer alleinigen Androgendeprivationstherapie (ADT) behandelt werden, mahnt ein US-Team nach Sichtung der aktuellen Datenlage. Mit einer Tripeltherapie haben die Betroffenen offenbar die besten Überlebenschancen.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.